Abstract
Nicotinamide adenine dinucleotide (NAD+) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD+ stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to intracellular NAD+ depletion and, when protracted, to ATP shortage and cell demise. Cancer cells and activated immune cells express high levels of NAMPT and are highly susceptible to NAMPT inhibitors, as shown by the activity of these agents in models of malignant and inflammatory disorders. As the spectrum of conditions which could benefit from pharmacological NAMPT inhibition becomes broader, the mechanisms accounting for their activity are also eventually becoming apparent, including the induction of autophagy and the impairment of Ca2+- and NF-κB-dependent signaling. Here, we discuss the rationales for exploiting NAMPT inhibitors in cancer and inflammatory diseases and provide an overview of the preclinical and clinical studies in which these agents have been evaluated.
Keywords: NAD+, NAMPT, sirtuins, cancer, inflammation, cardiovascular disorders, chemotaxis, angiogenesis.
Current Drug Targets
Title:Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Volume: 14 Issue: 6
Author(s): By Fabrizio Montecucco, Michele Cea, Inga Bauer, Debora Soncini, Irene Caffa, Denise Lasiglie, Aimable Nahimana, Antonio Uccelli, Santina Bruzzone and Alessio Nencioni
Affiliation:
Keywords: NAD+, NAMPT, sirtuins, cancer, inflammation, cardiovascular disorders, chemotaxis, angiogenesis.
Abstract: Nicotinamide adenine dinucleotide (NAD+) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD+ stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to intracellular NAD+ depletion and, when protracted, to ATP shortage and cell demise. Cancer cells and activated immune cells express high levels of NAMPT and are highly susceptible to NAMPT inhibitors, as shown by the activity of these agents in models of malignant and inflammatory disorders. As the spectrum of conditions which could benefit from pharmacological NAMPT inhibition becomes broader, the mechanisms accounting for their activity are also eventually becoming apparent, including the induction of autophagy and the impairment of Ca2+- and NF-κB-dependent signaling. Here, we discuss the rationales for exploiting NAMPT inhibitors in cancer and inflammatory diseases and provide an overview of the preclinical and clinical studies in which these agents have been evaluated.
Export Options
About this article
Cite this article as:
Montecucco By Fabrizio, Cea Michele, Bauer Inga, Soncini Debora, Caffa Irene, Lasiglie Denise, Nahimana Aimable, Uccelli Antonio, Bruzzone Santina and Nencioni Alessio, Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060003
DOI https://dx.doi.org/10.2174/1389450111314060003 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design Regulatory Role of Anesthetics on Heme Oxygenase-1
Current Drug Targets Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion Injury
Current Vascular Pharmacology Respiratory Hypoxia and Oxidative Stress in the Brain. Is the Endogenous Erythropoietin an Antioxidant?
Current Chemical Biology Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Novel Oral Anticoagulants in Peripheral Arterial and Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice
Current Cardiology Reviews Latest Advances in Hydrogel-Based Drug Delivery Systems for Optimization of Metabolic Syndrome Treatment
Current Medicinal Chemistry Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Does Erythropoietin Always Win?
Current Medicinal Chemistry The Role of Mitochondria in Piperine Mediated Cardioprotection in Isoproterenol Induced Myocardial Ischemia
Current Pharmaceutical Design Dexmedetomidine: A Review of its Use for the Management of Pain, Agitation, and Delirium in the Intensive Care Unit
Current Pharmaceutical Design Inotropic Therapies in Asphyxiated Neonates: The Clinical and Laboratory Facts
Current Pediatric Reviews Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design